Patents by Inventor Melanie SPEARS

Melanie SPEARS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and devices for predicting anthracycline treatment efficacy
    Patent number: 11214836
    Abstract: The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: January 4, 2022
    Assignee: Ontario Institute for Cancer Research
    Inventors: Melanie Spears, John Bartlett, Fouad Yousif, Paul Boutros
  • Targeting the histone pathway to detect and overcome anthracyclin resistance
    Patent number: 11015226
    Abstract: There is provided herein a method for determining a likelihood of resistance to anthracyclin, or poor survival, in a patient with cancer by identifying upregulation of at least one histone gene in the patient.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: May 25, 2021
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Melanie Spears, John M. Bartlett, Marsela Braunstein, Paul M. Krzyzanowski, Irina Kalatskaya, Lincoln Stein
  • Targeting the Histone Pathway to Detect and Overcome Anthracyclin Resistance
    Publication number: 20180282819
    Abstract: There is provided herein a method for determining a likelihood of resistance to anthracyclin, or poor survival, in a patient with cancer by identifying upregulation of at least one histone gene in the patient.
    Type: Application
    Filed: October 4, 2016
    Publication date: October 4, 2018
    Inventors: Melanie Spears, John M. Bartlett, Marsela Braunstein, Paul M. Krzyzanowski, Irina Kalatskaya, Lincoln Stein
  • METHODS AND DEVICES FOR PREDICTING ANTHRACYCLINE TREATMENT EFFICACY
    Publication number: 20170175204
    Abstract: The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.
    Type: Application
    Filed: July 15, 2015
    Publication date: June 22, 2017
    Inventors: Melanie SPEARS, John BARTLETT, Fouad YOUSIF, Paul BOUTROS